Postconfluent multilayered cell line cultures for selective screening of gemcitabine

European Journal of Cancer

Volumn 34, Issue 6, 1998, Pages 921-926

  Smitskamp Wilms, E ^a   Pinedo, H M ^a   Veerman, G ^a   Ruiz Van Haperen, V W T ^b,c   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c European Cancer Centre   (Netherlands)

Author keywords

Colon cancer; Gemcitabine; Ovarian cancer; Three dimensional cultures

Indexed keywords

GEMCITABINE; GEMCITABINE TRIPHOSPHATE;

ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; OVARY CANCER; PREDICTION; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; NUCLEOTIDES; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032078902     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10125-3     Document Type: Article

References (30)

1. Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumour activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990, 50, 4417-4422.
2. Braakhuis BJM, Van Dongen GMAS, Vermorken JB, Snow GB. Preclinical in vivo activity of 2′, 2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 1991, 51, 211-214.
3. Boven E, Schipper H, Erkelens CAM, Hatty SA, Pinedo HM. The influence of schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 1993,68, 52-56.
4. Merriman RL, Hertel LW, Schultz RM, et al. Comparison of the antitumor effect of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Investigational New Drugs 1996, 14, 243-247.
5. Lund B, Kristjanssen PEG, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993, 19,45-55.
6. Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol 1994, 12, 1527-1531.
7. Lund B, Hansen OP, Neijt JP, Theilade K, Hansen M. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anti-cancer Drugs 1995, 6(Suppl. 6), 61-62.
8. Van Moorsel CJA, Peters GJ, Pinedo HM. Gemcitabine: future prospects of single agent combination studies. Oncologist 1997, 2, 127-134.
9. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991, 51, 6110-6117.
10. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Peters GJ. 2′,2′-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 1993, 46, 762-766.
11. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 1988, 48, 4024-4031.
12. Ruiz van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ. Schedule dependency of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 1994, 48, 13271339.
13. Peters GJ, Plunkett W. Introduction. Gemcitabine-Status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog. Semin Oncol 1995, 22 (Suppl. 11), 1-2.
14. Heinemann V, Schulz L, Issels RD, Plunkett W. Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 1995, 22(Suppl. 11), 11-18.
15. Heinemann V, Xu Y-Z, Chubb S, et al. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of selfpotentiation. Cancer Res 1992, 52, 533-539.
16. Plunkett W, Huang P, Xu Y-Z, Heinemann V, Grunewald R, Gandhi V. Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995, 22(Suppl. 11), 3-10.
17. Plunkett W, Gandhi V, Chubb S, et al 2′,2′-Difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides Nucleotides 1989, 8, 775-785.
18. Pizao PE, Lyaruu DM, Peters GJ, et al. Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiterplates. BrJ Cancer 1992, 66, 660-665.
19. Pizao PE, Peters GJ, Van Ark-Otte J, et al. Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures. EurJ Cancer 1993, 29A, 1566-1573.
20. Skehan P, Storeng P, Scudiero D, et al. New calorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82, 1107-1112.
21. Keepers YP, Pizao PE, Peters GJ, Van Ark-otte J, Winograd B, Pinedo HM. Comparison of the sulphorhodamine B protein and tetrazolium (MTT) assay for in vitro chemosensitivity testing. EurJ Cancer 1991, 27, 897-900.
22. Boyd MR, Paull KD, Rubenstein L. Data display and analysis strategies for the NC1 disease-oriented in vitro drug screen. In Valeriote FA, Corbett TH, Baker LH eds. Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. Boston, Kluwer, 1992, 11-34.
23. Pizao PE, Smitskamp-Wilms E, Van Ark-Otte J, et al. Antiproliferative activity of the topoisomerase I inhibitors Topotecan and camptothecin on sub- and postconfluent tumor cell cultures. Biochem Pharmacol 1994, 48, 1145-1154.
24. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anti-Cancer Drugs 1995, 6(Suppl. 6), 7-13.
25. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Pinedo HM, Peters GJ. Regulatory effects of CTP and UTP on deoxycytidine kinase activity in solid tumor cell lines. Biochem Pharmacol 1996, 51, 911-918.
26. Braakhuis BJM, Ruiz van Haperen VWT, Boven E, Veerman G, Peters GJ. Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol 1995, 22(4, Suppl. 11), 42-46.
27. Ruiz van Haperen VWT, Veerman G, Eriksson S, et al. Development and characterization of a 2′,2′-difluorodeoxycytidineresistant variant of the human ovarian cancer cell line A2780. Cancer Res 1994, 54, 4138-4143.
28. Gandhi V, Plunkett W. Modulatory activity of 2′,2′-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 1990, 50, 3675-3680.
29. Shewach DS, Hahan TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994, 54, 3218-3223.
30. Rustum YM, Preisler HD. Correlation between leukaemic cell retention of 1-β-D-arabinofuranosylcytosine-5′-triphosphate and response to therapy. Cancer Res 1979, 39, 42-49.